Washington, D.C. – Senator Tom Cotton (R-Arkansas) released the following statement on the Supreme Court’s refusal to hear an appeal by Allergan regarding the company’s attempted purchase of sovereign immunity from an Indian tribe for the drug Restasis:
“The Supreme Court’s decision is a victory for Arkansas seniors and all Americans who are hurting from the high price of prescription drugs. The drug company’s attempt to buy sovereign immunity from an Indian tribe was a sham, and I am glad that the scheme has failed.”
Background: In 2017, Allergan sold the patents to its dry-eye medication Restasis to the St. Regis Mohawk Tribe in an attempt to use the tribe’s sovereign immunity to avoid a review of the validity of the patents.
Senator Cotton introduced the Preserving Access to Cost-Effective Drugs Act (PACED) Act in response to Allergan’s attempt to purchase sovereign immunity to protect its patents and keep drug prices high. The PACED Act would prohibit patent-holders from using tribal sovereign immunity as a defense in proceedings before the U.S. Patent Office, the courts, and the International Trade Commission.
Original article source: http://www.cotton.senate.gov?p=press_release&id=1107 | Article may or may not reflect the views of KLEK 102.5 FM or The Voice of Arkansas Minority Advocacy Council